The Latest Trading Price of Anuh Pharma Ltd is ₹ 85.43 as of 05 May 15:30
. The P/E Ratio of Anuh Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 years The Market Cap of Anuh Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 years The revenue of Anuh Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The ebitda of Anuh Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The net profit of Anuh Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39%
The Dividend Payout of Anuh Pharma Ltd changed from 26.43 % on March 2021 to 15.88 % on March 2025 . This represents a CAGR of -9.69% over 5 yearsThe Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 years .
About Anuh Pharma Ltd
Anuh Pharma Limited is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs).
The Company is engaged in the business of manufacturing and selling of 'Bulk drugs and chemicals.
The company is part of the SK Group with the key products including antibiotics, erythromycin salts, chloramphenicol and other chemicals.
It is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.
The Company was incorporated on February 19, 1960.
The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra.
About Kopran Ltd
Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.
FAQs for the comparison of Anuh Pharma Ltd and Kopran Ltd
Which company has a larger market capitalization, Anuh Pharma Ltd or Kopran Ltd?
Market cap of Anuh Pharma Ltd is 856 Cr while Market cap of Kopran Ltd is 782 Cr
What are the key factors driving the stock performance of Anuh Pharma Ltd and Kopran Ltd?
The stock performance of Anuh Pharma Ltd and Kopran Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Anuh Pharma Ltd and Kopran Ltd?
As of May 5, 2026, the Anuh Pharma Ltd stock price is INR ₹85.43. On the other hand, Kopran Ltd stock price is INR ₹162.1.
How do dividend payouts of Anuh Pharma Ltd and Kopran Ltd compare?
To compare the dividend payouts of Anuh Pharma Ltd and Kopran Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.